PET-ONLY 18F-AV1451 TAU QUANTIFICATION

被引：0

作者：

Bourgeat, P. ^{[1
]}

Villemagne, V. L. ^{[2
,4
]}

Dore, V. ^{[1
,4
]}

Masters, C. L. ^{[2
]}

Ames, D. ^{[3
]}

Rowe, C. C. ^{[4
]}

Salvado, O. ^{[1
]}

Fripp, J. ^{[1
]}

机构：

[1] CSIRO, Hlth & Biosecur, Canberra, ACT, Australia

[2] Mental Hlth Res Inst, Parkville, Vic, Australia

[3] Natl Ageing Res Inst, Parkville, Vic, Australia

[4] Dept Nucl Med & Ctr PET, Parkville, Vic, Australia

来源：

2017 IEEE 14TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI 2017) | 2017年

基金：

美国国家卫生研究院; 加拿大健康研究院;

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

In vivo tau imaging with PET is a promising new modality that offers a unique insight into Alzheimer's disease (AD) pathology. F-18-AV1451 is a tau tracer currently being evaluated in both AIBL and ADNI. While MR-based quantification remains the gold standard, there is great interest in PET-only quantification techniques for use in patients who cannot undergo MRI. In this study, 3 PET-only methods (single atlas, adaptive atlas, and PCA-based atlas) are evaluated and compared to an MR-based quantification in both AIBL (94 subjects) and ADNI (87 subjects). Results show that all quantifications performed using PET-only normalization approaches did equally well, with an average quantification error around 2% in both cohorts.

引用

页码：1173 / 1176

页数：4

共 50 条

[31] Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech
Utianski, Rene L.
Whitwell, Jennifer L.
Schwarz, Christopher G.
Senjem, Matthew L.
Tosakulwong, Nirubol
Duffy, Joseph R.
Clark, Heather M.
Machulda, Mary M.
Petersen, Ronald C.
Jack, Clifford R., Jr.
Lowe, Val J.
Josephs, Keith A.
CORTEX, 2018, 99 : 358 - 374
[32] Diagnostic utility of regional [18F] AV-1451 tau-PET measurements in PSP
Whitwell, J.
Lowe, V.
Tosakulwong, N.
Weigand, S.
Senjem, M.
Schwarz, C.
Spychalla, A.
Petersen, R.
Jack, C.
Josephs, K.
MOVEMENT DISORDERS, 2017, 32
[33] Examining iron-related off-target binding effects of 18F-AV1451 PET in the cortex of Aβ plus individuals
Langley, Jason
Bennett, Ilana J.
Hu, Xiaoping P.
EUROPEAN JOURNAL OF NEUROSCIENCE, 2024, 60 (01) : 3614 - 3628
[34] Comparing quantitative measures of global and regional tau binding for 18F AV-1451 PET scans
Chen, Jingyun
Li, Yi
Pirraglia, Elizabeth
Rusinek, Henry
De Leon, Mony
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[35] PET Imaging of a Transgenic Tau Rat Model SHR24 with [18F]AV1451
Ramakrishnan, Nisha K.
Zhao, Annie Ziyi
Thompson, Stephen
Sephton, Selena Milicevic
Williamson, David J.
Smolek, Tomas
Zilka, Norbert
Aigbirhio, Franklin I.
MOLECULAR IMAGING AND BIOLOGY, 2025,
[36] [18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer's disease
Rowe, J. B.
Rodriguez, P. Vazquez
Hong, Y. T.
Borchert, R. J.
Sami, S.
Bevan-Jones, W. R.
Jones, S. P.
Arnold, R.
Surendranathan, A.
Mak, E.
Li, S.
Fryer, T.
O'Brien, J.
Passamonti, L.
MOVEMENT DISORDERS, 2016, 31 : S375 - S376
[37] Imaging tau Pathology In Vivo in AD and FTLD Spectrum Tauopathies with [18F] AV1451 PET
Dickerson, Bradford
Makaretz, Sara
Caso, Christina
Stepanovic, Michael
Quimby, Megan
Xia, Chenjie
McCinnis, Scott
Frosc, Matthew
Johnson, Keith
NEUROLOGY, 2016, 86
[38] Increased retention of tau PET ligand [18F]-AV1451 in Alzheimer's Disease Psychosis
Gomar, J. J.
Tan, G.
Halpern, J.
Gordon, M. L.
Greenwald, B.
Koppel, J.
TRANSLATIONAL PSYCHIATRY, 2022, 12 (01)
[39] Principal component analysis of [18F]-AV-1451 tau PET in Alzheimer disease and frontotemporal dementia
Friedrichsen, K.
Mishra, S.
Ghoshal, N.
Gordon, B.
Joseph-Mathurin, N.
Su, Y.
Christensen, J.
Aldea, P.
McConathy, J.
Ances, B.
Cairns, N.
Morris, J.
Benzinger, T.
JOURNAL OF NEUROCHEMISTRY, 2016, 138 : 383 - 384
[40] Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease
Mattsson, Niklas
Insel, Philip S.
Donohue, Michael
Jogi, Jonas
Ossenkoppele, Rik
Olsson, Tomas
Scholl, Michael
Smith, Ruben
Hansson, Oskar
ALZHEIMERS & DEMENTIA, 2019, 15 (04) : 570 - 580

← 1 2 3 4 5 →